Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 5:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–16 of 16 matching trials from the live ClinicalTrials.gov search.
Conditions
Advanced Soft Tissue Sarcoma, Locally Advanced Soft Tissue Sarcoma, Metastatic Soft Tissue Sarcoma
Interventions
Sirolimus Albumin-bound Nanoparticles, Pazopanib hydrochloride
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Endometrial Cancer, Endometrioid Tumor, Cancer, Tumor, Recurrent Endometrial Carcinoma, Endometrioid Endometrial Cancer
Interventions
nab-sirolimus
Drug
Lead sponsor
Aadi Bioscience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
9
States / cities
Little Rock, Arkansas • Miami Beach, Florida • Las Vegas, Nevada + 6 more
Conditions
High Grade Recurrent Glioma and Newly Diagnosed Glioblastoma
Interventions
nab-sirolimus, nab-sirolimus + temozolomide, nab-sirolimus + bevacizumab, nab-sirolimus + lomustine, nab-sirolimus + marizomib (MRZ), nab-sirolimus + temozolomide + radiotherapy
Drug
Lead sponsor
Aadi Bioscience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
3
States / cities
Fullerton, California • Newport Beach, California • Santa Monica, California
Conditions
Tumor, Solid, Tumor, Advanced Solid Tumor
Interventions
nab-sirolimus
Drug
Lead sponsor
Aadi Bioscience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
San Antonio, Texas • West Valley City, Utah
Conditions
Tumor, Tumor, Solid, Metastasis, Metastatic Cancer, Cancer, Cancer Metastatic, Tumors, Neoplasms, Neoplasm Metastasis, Solid Tumor, Advanced Solid Tumor, Advanced Cancer, Malignant Solid Tumor, Malignant Solid Neoplasm, Malignant Neoplasm, Malignant Tumor, TSC, TSC1, TSC2, Metastatic Solid Tumor, Metastatic Neoplasm
Interventions
nab-sirolimus
Drug
Lead sponsor
Aadi Bioscience, Inc.
Industry
Eligibility
12 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
159
States / cities
Birmingham, Alabama • Mobile, Alabama • Goodyear, Arizona + 137 more
Conditions
Solid Tumor, Adult, NSCLC, Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease
Interventions
Adagrasib, nab-Sirolimus
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
3
States / cities
Cleveland, Ohio • Nashville, Tennessee • Houston, Texas
Conditions
Ewing Sarcoma, PEComa, Epithelioid Sarcoma, Desmoid Tumor, Chordoma, Non Small Cell Lung Cancer, Urothelial Carcinoma, Melanoma, Renal Cell Carcinoma, Squamous Cell Carcinoma, Hepatocellular Carcinoma, Classical Hodgkin Lymphoma, Colorectal Cancer, MTOR Activating Mutation
Interventions
Nab-Rapamycin, Nivolumab
Drug · Biological
Lead sponsor
Sarcoma Oncology Research Center, LLC
Other
Eligibility
12 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Santa Monica, California
Conditions
Multiple Myeloma
Interventions
ABI-009, Pomalidomide, Dexamethasone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Pulmonary Hypertension
Interventions
nab-sirolimus
Drug
Lead sponsor
Aadi Bioscience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
6
States / cities
Tucson, Arizona • Torrance, California • Indianapolis, Indiana + 3 more
Conditions
Malignant PEComa
Interventions
nab-Sirolimus
Drug
Lead sponsor
Aadi Bioscience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
9
States / cities
Palo Alto, California • Santa Monica, California • Boston, Massachusetts + 6 more
Conditions
Colorectal Cancer Metastatic
Interventions
nab-sirolimus
Drug
Lead sponsor
Aadi Bioscience, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
6
States / cities
Scottsdale, Arizona • New Orleans, Louisiana • Las Vegas, Nevada + 3 more
Completed Phase 1Phase 2 Interventional Results available

Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer

NCT02009332
Conditions
Non-muscle Invasive Bladder Cancer (NMIBC)
Interventions
ABI-009, Gemcitabine
Drug
Lead sponsor
Aadi Bioscience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
2
States / cities
New York, New York • Nashville, Tennessee
Conditions
Epilepsy Intractable
Interventions
ABI-009
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
3 Years to 26 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Neuroendocrine Tumors, NET, Pancreatic Neuroendocrine Tumor, Gastrointestinal Neuroendocrine Tumor, Pulmonary Neuroendocrine Tumor
Interventions
nab-sirolimus
Drug
Lead sponsor
Aadi Bioscience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
4
States / cities
Newport Beach, California • Denver, Colorado • Dallas, Texas + 1 more
Conditions
Neuroendocrine Tumors
Interventions
ABI-009
Drug
Lead sponsor
Robert Ramirez
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
New Orleans, Louisiana
Conditions
Low Grade Ovarian Serous Adenocarcinoma
Interventions
nab-Sirolimus, Fulvestrant
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older · Female only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Oklahoma City, Oklahoma